Lilly Takes on Vertex in Non-Opioid Pain with SiteOne Buy

Lilly takes on Vertex in non-opioid pain with SiteOne buy

Lilly buys SiteOne in a $1bn deal that would give it a rival to Vertex's approved painkiller Journavx, and a partnership on another programme

Lilly to buy pain drug developer SiteOne, challenging Vertex

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Lilly Acquires SiteOne Therapeutics

Eli Lilly and Company (NYSE: LLY) acquired SiteOne Therapeutics, Inc., a San Francisco, CA-based private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders. The amount of the deal was not disclosed. With the acquisition, Lilly will augment its efforts to advance non-opioid medicines for pain management. The […] The post Lilly Acquires SiteOne Therapeutics app…

Lilly Inks $1B Deal for Next-Gen Pain Treatment

Eli Lilly and Company (NYSE: LLY) today announced that it has entered into a definitive agreement to acquire SiteOne Therapeutics, a privately held biotech company focused on developing non-opioid pain therapies, in a transaction valued at up to $1 billion. This Eli Lilly $1B deal non-opioid pain drug acquisition expands Lilly’s neuroscience pipeline and reinforces its commitment to delivering innovative, addiction-free treatments for chronic pa…

Eli Lilly Acquires SiteOne Therapeutics to Advance Non-Opioid Pain Treatments

Eli Lilly has announced the acquisition of SiteOne Ther […] The post Eli Lilly Acquires SiteOne Therapeutics to Advance Non-Opioid Pain Treatments first appeared on GeneOnline News. The post Eli Lilly Acquires SiteOne Therapeutics to Advance Non-Opioid Pain Treatments appeared first on GeneOnline News.

Eli Lilly to expand pain pipeline with $1bn SiteOne buyout - Pharmaceutical Technology

The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids.